DaVita (DVA) Stock Price, News & Analysis

Company Overview

DaVita Inc. (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions. The company’s growth has broadened its footprint across the United States and into select international markets, enabling it to serve a diverse patient population. DaVita leverages clinical protocols, integrated care teams and telehealth capabilities to enhance treatment consistency and improve health outcomes.

DaVita places a strong emphasis on clinical quality and patient-centered care, operating under stringent regulatory standards and collaborating closely with physicians, hospitals and payers. The company has introduced various initiatives aimed at reducing hospitalization rates, managing complications and promoting patient independence through home therapies. Its data-driven approach supports continuous improvement in care delivery and resource utilization across its network of facilities.

The company’s leadership team is headed by President and Chief Executive Officer Javier Rodriguez, who oversees DaVita’s strategic direction and operational execution. Under his guidance, DaVita continues to pursue innovations in kidney care, digital health and value-based care models, with the goal of advancing treatment accessibility and driving long-term sustainability in the renal healthcare market.

Key Stats

• Today's Range: $193.85 to $199.27
• 50-Day Range: $144.41 to $195.96
• 52-Week Range: $101.00 to $199.27
• Volume: 306,282 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $12.61 billion
• P/E Ratio: 18.18
• Dividend Yield: N/A
• Price Target: $180.00
• Consensus Rating: Hold

DaVita Stock Analysis - MarketRank™

DaVita scored higher than 67% of companies evaluated by MarketBeat, and ranked 326th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Hold

Consensus Rating

DaVita has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and 1 sell rating.

Downside Risk

DaVita has a consensus price target of $180.00, representing about 8.1% downside from its current price of $195.84.

Amount of Analyst Coverage

DaVita has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 16.98%

Earnings Growth

Earnings for DaVita are expected to grow by 16.98% in the coming year, from $14.49 to $16.95 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DaVita is 18.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of DaVita is 18.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.72.

Price to Earnings Growth Ratio

DaVita has a PEG Ratio of 0.66. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.99% of the float of DaVita has been sold short.

Short Interest Ratio / Days to Cover

DaVita has a short interest ratio ("days to cover") of 8.61.

Change versus previous month

Short interest in DaVita has recently decreased by 4.34%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DaVita does not currently pay a dividend.

Dividend Growth

DaVita does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.92

News Sentiment

DaVita has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for DaVita this week, compared to 5 articles on an average week.

Search Interest

15 people have searched for DVA on MarketBeat in the last 30 days. This is an increase of 650% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DaVita insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of DaVita is held by insiders.

Percentage Held by Institutions

90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/08/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:DVA
• CIK: 927066
• Web: www.davita.com
• Phone: (720) 631-2100
• Fax: 302-636-5454
• Employees: 78,000
• Year Founded: 1994

Price Target and Rating

• Average Price Target for DaVita: $180.00
• High Price Target: $235.00
• Low Price Target: $133.00
• Potential Upside/Downside: -8.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $9.91
• Trailing P/E Ratio: 18.10
• Forward P/E Ratio: 13.52
• P/E Growth: 0.66
• Net Income: $746.80 million
• Net Margins: 5.65%
• Pretax Margin: 10.13%
• Return on Equity: -270.37%
• Return on Assets: 4.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.42
• Quick Ratio: 1.24

Sales & Book Value

• Annual Sales: $13.64 billion
• Price / Sales: 0.92
• Cash Flow: $21.93 per share
• Price / Cash Flow: 8.93
• Book Value: ($7.42) per share
• Price / Book: -26.39

Miscellaneous

• Outstanding Shares: 64,200,000
• Free Float: 65,798,000
• Market Cap: $12.57 billion
• Optionable: Optionable
• Beta: 0.84